Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare Therapeutics Announces Positive Results from Lunresertib, Camonsertib Combo Trial
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Repare Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic
Details : The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 06, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Repare Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare Shares Positive Phase 1 Data From MYTHIC Safety and Tolerability Study
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Debio 0123
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Debiopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare and Debiopharm Dosed First Patient in Phase 1/1b MYTHIC Trial
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : Lunresertib,Debio 0123
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Debiopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare's Lunresertib Gets FDA Fast Track for Platinum-Resistant Ovarian Cancer
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123,Lunresertib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Debiopharm Partners with Repare To Explore PKMYT1 and WEE1 Inhibition
Details :
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Debio 0123,Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Canadian Cancer Trials Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Canadian Cancer Trials Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable